Mathieu Vinken

List of Publications by Year
in descending order

200 papers	9,152 citations	66250 44 h-index	58552 86 g-index
207 all docs	207 docs citations	207 times ranked	10979 citing authors

#	Article	IF	Citations
1	Systematic comparison of experimental and human obstructive cholestasis reveals conservation of canonical pathway activation and biomarkers relevant for cholestatic liver disease. Genes and Diseases, 2023, 10, 18-21.	1.5	1
2	Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing. Methods in Molecular Biology, 2022, 2425, 521-535.	0.4	2
3	Assessing Safety Without Animal Testing: The Road Ahead. Toxicological Sciences, 2022, 187, 214-218.	1.4	9
4	Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods. International Journal of Molecular Sciences, 2022, 23, 3315.	1.8	33
5	Advances in Animal Models and Cutting-Edge Research in Alternatives: Proceedings of the Second International Conference on 3Rs Research and Progress, Hyderabad, 2021. ATLA Alternatives To Laboratory Animals, 2022, , 026119292210892.	0.7	4
6	Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. International Journal of Molecular Sciences, 2022, 23, 5018.	1.8	1
7	Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels. International Journal of Molecular Sciences, 2022, 23, 5664.	1.8	1
8	Adverse outcome pathway from activation of the AhR to breast cancer-related death. Environment International, 2022, 165, 107323.	4.8	24
9	Hepatotoxicity induced by nanomaterials: mechanisms and in vitro models. Archives of Toxicology, 2021, 95, 27-52.	1.9	23
10	Primary hepatocyte cultures for liver disease modeling. Current Opinion in Toxicology, 2021, 25, 1-5.	2.6	7
11	A Robust, Mechanistically Based <i>In Silico</i> Structural Profiler for Hepatic Cholestasis. Chemical Research in Toxicology, 2021, 34, 641-655.	1.7	6
12	Sorafenib reduces steatosisâ€induced fibrogenesis in a human 3D coâ€culture model of nonâ€alcoholic fatty liver disease. Environmental Toxicology, 2021, 36, 168-176.	2.1	12
13	Rodent models of cholestatic liver disease: A practical guide for translational research. Liver International, 2021, 41, 656-682.	1.9	28
14	Mechanisms Underlying Connexin Hemichannel Activation in Disease. International Journal of Molecular Sciences, 2021, 22, 3503.	1.8	27
15	Biomarkers of cholestasis. Biomarkers in Medicine, 2021, 15, 437-454.	0.6	11
16	In Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach. International Journal of Molecular Sciences, 2021, 22, 5038.	1.8	18
17	COVID-19 and the liver: an adverse outcome pathway perspective. Toxicology, 2021, 455, 152765.	2.0	8
18	An overview of current practices for regulatory risk assessment with lessons learnt from cosmetics in the European Union. Critical Reviews in Toxicology, 2021, 51, 395-417.	1.9	8

#	Article	IF	Citations
19	Safer chemicals using less animals: kick-off of the European ONTOX project. Toxicology, 2021, 458, 152846.	2.0	33
20	Testing in vitro tools for the prediction of cholestatic liver injury induced by non-pharmaceutical chemicals. Food and Chemical Toxicology, 2021, 152, 112165.	1.8	7
21	Derivation, characterisation and analysis of an adverse outcome pathway network for human hepatotoxicity. Toxicology, 2021, 459, 152856.	2.0	25
22	Bosentan alters endo- and exogenous bile salt disposition in sandwich-cultured human hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, JPET-AR-2021-000695.	1.3	2
23	Dataset on transcriptomic profiling of cholestatic liver injury induced by food additives and a cosmetic ingredient. Data in Brief, 2021, 38, 107373.	0.5	1
24	Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor. Biomolecules, 2021, 11, 63.	1.8	13
25	Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. International Journal of Molecular Sciences, 2021, 22, 11005.	1.8	6
26	Connexin-Based Channel Activity Is Not Specifically Altered by Hepatocarcinogenic Chemicals. International Journal of Molecular Sciences, 2021, 22, 11724.	1.8	3
27	In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling. Cancers, 2021, 13, 5583.	1.7	18
28	Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines. International Journal of Molecular Sciences, 2021, 22, 12187.	1.8	7
29	Connexin Hemichannels. , 2021, , 478-483.		0
30	Cholestatic liver injury induced by food additives, dietary supplements and parenteral nutrition. Environment International, 2020, 136, 105422.	4.8	18
31	Burdock (<scp><i>Arctium lappa</i></scp> L.) root attenuates preneoplastic lesion development in a diet and thioacetamideâ€induced model of steatohepatitisâ€associated hepatocarcinogenesis. Environmental Toxicology, 2020, 35, 518-527.	2.1	14
32	Dataset on transcriptomic profiling of cholestatic liver injury in an in vitro and in vivo animal model. Data in Brief, 2020, 32, 106156.	0.5	3
33	A putative AOP for pneumonia related to COVID-19. Archives of Toxicology, 2020, 94, 3343-3345.	1.9	8
34	Astrocytic Connexin43 Channels as Candidate Targets in Epilepsy Treatment. Biomolecules, 2020, 10, 1578.	1.8	27
35	The combination of coffee compounds attenuates early fibrosis-associated hepatocarcinogenesis in mice: involvement of miRNA profile modulation. Journal of Nutritional Biochemistry, 2020, 85, 108479.	1.9	13
36	Canonical and Non-Canonical Roles of Connexin43 in Cardioprotection. Biomolecules, 2020, 10, 1225.	1.8	24

#	Article	IF	Citations
37	Screening of repeated dose toxicity data in safety evaluation reports of cosmetic ingredients issued by the Scientific Committee on Consumer Safety between 2009 and 2019. Archives of Toxicology, 2020, 94, 3723-3735.	1.9	6
38	Cholestasis Differentially Affects Liver Connexins. International Journal of Molecular Sciences, 2020, 21, 6534.	1.8	9
39	Targeting gap junctional intercellular communication by hepatocarcinogenic compounds. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2020, 23, 255-275.	2.9	4
40	Peptide-based targeting of connexins and pannexins for therapeutic purposes. Expert Opinion on Drug Discovery, 2020, 15, 1213-1222.	2.5	14
41	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Archives of Toxicology, 2020, 94, 1151-1172.	1.9	28
42	Non-canonical roles of connexins. Progress in Biophysics and Molecular Biology, 2020, 153, 35-41.	1.4	14
43	The use of adverse outcome pathways in the safety evaluation of food additives. Archives of Toxicology, 2020, 94, 959-966.	1.9	18
44	New ideas for non-animal approaches to predict repeated-dose systemic toxicity: Report from an EPAA Blue Sky Workshop. Regulatory Toxicology and Pharmacology, 2020, 114, 104668.	1.3	33
45	3Rs toxicity testing and disease modeling projects in the European Horizon 2020 research and innovation program. EXCLI Journal, 2020, 19, 775-784.	0.5	12
46	Liver Adverse Outcome Pathways: Whatâ€™s in for the Hepatologist?. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 659-664.	0.5	1
47	Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs. Archives of Toxicology, 2019, 93, 2115-2125.	1.9	17
48	Current insights in the complexities underlying drug-induced cholestasis. Critical Reviews in Toxicology, 2019, 49, 520-548.	1.9	17
49	Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation. Biomolecules, 2019, 9, 636.	1.8	4
50	Key performance indicators of the contemporary European academic toxicologist. Archives of Toxicology, 2019, 93, 1775-1776.	1.9	0
51	Drinking for protection? Epidemiological and experimental evidence on the beneficial effects of coffee or major coffee compounds against gastrointestinal and liver carcinogenesis. Food Research International, 2019, 123, 567-589.	2.9	36
52	Industrial, Biocide, and Cosmetic Chemical Inducers of Cholestasis. Chemical Research in Toxicology, 2019, 32, 1327-1334.	1.7	16
53	Mechanisms of Drug-Induced Cholestasis. Methods in Molecular Biology, 2019, 1981, 1-14.	0.4	10
54	Establishment of Sandwich Cultures of Primary Human Hepatocytes. Methods in Molecular Biology, 2019, 1981, 325-333.	0.4	8

#	Article	IF	Citations
55	What is understood by â€œanimal-free researchâ€?. Toxicology in Vitro, 2019, 57, 143-144.	1.1	7
56	The role and therapeutic potential of connexins, pannexins and their channels in Parkinson's disease. Cellular Signalling, 2019, 58, 111-118.	1.7	24
57	The use of social media in scientific research and creative thinking. Toxicology in Vitro, 2019, 59, 51-54.	1.1	6
58	Mechanisms and in vitro models of drug-induced cholestasis. Archives of Toxicology, 2019, 93, 1169-1186.	1.9	25
59	A mode-of-action ontology model for safety evaluation of chemicals: Outcome of a series of workshops on repeated dose toxicity. Toxicology in Vitro, 2019, 59, 44-50.	1.1	19
60	Omics-based input and output in the development and use of adverse outcome pathways. Current Opinion in Toxicology, 2019, 18, 8-12.	2.6	23
61	Primary hepatocytes and their cultures for the testing of drug-induced liver injury. Advances in Pharmacology, 2019, 85, 1-30.	1.2	13
62	Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment of Liver Disease. Hepatology, 2019, 69, 1317-1323.	3.6	21
63	Cell junctions and oral health. EXCLI Journal, 2019, 18, 317-330.	0.5	14
64	<scp>I</scp>nhibition of astroglial connexin43 hemichannels with <scp>TAT</scp>â€‹<scp>G</scp>ap19 exerts anticonvulsant effects in rodents. Glia, 2018, 66, 1788-1804.	2.5	50
65	Taking adverse outcome pathways to the next level. Toxicology in Vitro, 2018, 50, A1-A2.	1.1	13
66	Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicology in Vitro, 2018, 48, 53-70.	1.1	62
67	Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 819-830.	1.8	22
68	In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist. Archives of Toxicology, 2018, 92, 1909-1912.	1.9	18
69	Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Archives of Toxicology, 2018, 92, 371-381.	1.9	32
70	Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Archives of Toxicology, 2018, 92, 1939-1952.	1.9	34
71	TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. International Journal of Molecular Sciences, 2018, 19, 817.	1.8	34
72	Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Archives of Toxicology, 2018, 92, 2517-2531.	1.9	46

#	Article	IF	Citations
73	Genetic ablation of pannexin1 counteracts liver fibrosis in a chemical, but not in a surgical mouse model. Archives of Toxicology, 2018, 92, 2607-2627.	1.9	11
74	Characterization of hepatocyte-based in vitro systems for reliable toxicity testing. Archives of Toxicology, 2018, 92, 2981-2986.	1.9	40
75	Calcium, oxidative stress and connexin channels, a harmonious orchestra directing the response to radiotherapy treatment?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1099-1120.	1.9	48
76	In vitro testing of basal cytotoxicity: Establishment of an adverse outcome pathway from chemical insult to cell death. Toxicology in Vitro, 2017, 39, 104-110.	1.1	64
77	Adverse outcome pathways: opportunities, limitations and open questions. Archives of Toxicology, 2017, 91, 3477-3505.	1.9	282
78	Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice. Scientific Reports, 2017, 7, 8268.	1.6	33
79	Inhibitors of connexin and pannexin channels as potential therapeutics. , 2017, 180, 144-160.		114
80	Connexin hemichannel inhibition reduces acetaminophen-induced liver injury in mice. Toxicology Letters, 2017, 278, 30-37.	0.4	31
81	Adverse outcome pathways: a concise introduction for toxicologists. Archives of Toxicology, 2017, 91, 3697-3707.	1.9	103
82	Inhibition of pannexin1 channels alleviates acetaminophen-induced hepatotoxicity. Archives of Toxicology, 2017, 91, 2245-2261.	1.9	16
83	Pannexin1 as mediator of inflammation and cell death. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 51-61.	1.9	85
84	Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental nonâ€alcoholic steatohepatitis. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 197-206.	0.9	16
85	Adverse outcome pathway development from protein alkylation to liver fibrosis. Archives of Toxicology, 2017, 91, 1523-1543.	1.9	41
86	Connexin-based signaling and drug-induced hepatotoxicity. Journal of Clinical and Translational Research, 2017, 3, 189-198.	0.3	5
87	An Update on Adverse Outcome Pathways Leading to Liver Injury. Applied in Vitro Toxicology, 2017, 3, 283-285.	0.6	16
88	Inhibition of Connexin43 Hemichannels Impairs Spatial Short-Term Memory without Affecting Spatial Working Memory. Frontiers in Cellular Neuroscience, 2016, 10, 288.	1.8	48
89	Connexin32 deficiency exacerbates carbon tetrachloride-induced hepatocellular injury and liver fibrosis in mice. Toxicology Mechanisms and Methods, 2016, 26, 362-370.	1.3	13
90	Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2231-40.	3.3	238

#	Article	IF	Citations
91	Detection of Connexins in Liver Cells Using Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis and Immunoblot Analysis. Methods in Molecular Biology, 2016, 1437, 37-53.	0.4	2
92	Analysis of Liver Connexin Expression Using Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction. Methods in Molecular Biology, 2016, 1437, 1-19.	0.4	4
93	Immunohisto- and Cytochemistry Analysis of Connexins. Methods in Molecular Biology, 2016, 1437, 55-70.	0.4	5
94	Connexins, Pannexins, and Their Channels in Fibroproliferative Diseases. Journal of Membrane Biology, 2016, 249, 199-213.	1.0	17
95	Connexins and their channels in inflammation. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 413-439.	2.3	93
96	Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity. Methods in Molecular Biology, 2016, 1425, 325-337.	0.4	14
97	Connexin32: a mediator of acetaminophen-induced liver injury?. Toxicology Mechanisms and Methods, 2016, 26, 88-96.	1.3	15
98	Involvement of connexin43 in acetaminophen-induced liver injury. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1111-1121.	1.8	29
99	Experimental models of hepatotoxicity related to acute liver failure. Toxicology and Applied Pharmacology, 2016, 290, 86-97.	1.3	160
100	Regulation of connexin signaling by the epigenetic machinery. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 262-268.	0.9	20
101	Experimental models of liver fibrosis. Archives of Toxicology, 2016, 90, 1025-1048.	1.9	243
102	Connexins and pannexins in liver damage. EXCLI Journal, 2016, 15, 177-86.	0.5	23
103	Connexin and pannexin signaling in gastrointestinal and liver disease. Translational Research, 2015, 166, 332-343.	2.2	42
104	Structure, Regulation and Function of Gap Junctions in Liver. Cell Communication and Adhesion, 2015, 22, 29-37.	1.0	18
105	Models and methods for in vitro testing of hepatic gap junctional communication. Toxicology in Vitro, 2015, 30, 569-577.	1.1	10
106	Connexin hemichannels: novel mediators of toxicity. Archives of Toxicology, 2015, 89, 143-145.	1.9	20
107	Introduction: connexins, pannexins and their channels as gatekeepers of organ physiology. Cellular and Molecular Life Sciences, 2015, 72, 2775-2778.	2.4	39
108	Making sense of in vitro methods. Proceedings of the 18th ESTIV congress. Toxicology in Vitro, 2015, 29, 1215-1216.	1.1	0

#	Article	IF	Citations
109	Connexin 43 deficiency accelerates skin wound healing and extracellular matrix remodeling in mice. Journal of Dermatological Science, 2015, 79, 50-56.	1.0	40
110	Roles of connexins and pannexins in digestive homeostasis. Cellular and Molecular Life Sciences, 2015, 72, 2809-2821.	2.4	32
111	Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Progress in Lipid Research, 2015, 59, 106-125.	5.3	130
112	Adverse Outcome Pathways and Drug-Induced Liver Injury Testing. Chemical Research in Toxicology, 2015, 28, 1391-1397.	1.7	76
113	MicroRNAs as key regulators of xenobiotic biotransformation and drug response. Archives of Toxicology, 2015, 89, 1523-1541.	1.9	16
114	Measurement of Apoptotic and Necrotic Cell Death in Primary Hepatocyte Cultures. Methods in Molecular Biology, 2015, 1250, 349-361.	0.4	39
115	Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes. Methods in Molecular Biology, 2015, 1250, 53-76.	0.4	41
116	Effects of Trichostatin A on drug uptake transporters in primary rat hepatocyte cultures. EXCLI Journal, 2015, 14, 567-76.	0.5	5
117	Development and characterization of a new human hepatic cell line. EXCLI Journal, 2015, 14, 875-89.	0.5	4
118	Establishment and Characterization of an In Vitro Model of Fas-Mediated Hepatocyte Cell Death. Methods in Molecular Biology, 2015, 1250, 95-103.	0.4	2
119	Toxicogenomics directory of chemically exposed human hepatocytes. Archives of Toxicology, 2014, 88, 2261-2287.	1.9	143
120	Connexin and pannexin (hemi)channels in the liver. Frontiers in Physiology, 2014, 4, 405.	1.3	45
121	Application of in silico and in vitro methods in the development of adverse outcome pathway constructs in wildlife. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130584.	1.8	25
122	Adverse outcome pathways: hype or hope?. Archives of Toxicology, 2014, 88, 1-2.	1.9	19
123	Primary hepatocytes and their cultures in liver apoptosis research. Archives of Toxicology, 2014, 88, 199-212.	1.9	32
124	The dual face of connexin-based astroglial Ca2+ communication: A key player in brain physiology and a prime target in pathology. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2211-2232.	1.9	74
125	Human Skin-Derived Stem Cells as a Novel Cell Source for In Vitro Hepatotoxicity Screening of Pharmaceuticals. Stem Cells and Development, 2014, 23, 44-55.	1.1	48
126	Way forward in case of a false positive in vitro genotoxicity result for a cosmetic substance?. Toxicology in Vitro, 2014, 28, 54-59.	1.1	19

#	Article	IF	Citations
127	Strategies for immortalization of primary hepatocytes. Journal of Hepatology, 2014, 61, 925-943.	1.8	86
128	Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 500-19.	0.9	13
129	Testing chemical carcinogenicity by using a transcriptomics HepaRG-based model?. EXCLI Journal, 2014, 13, 623-37.	0.5	18
130	Proteomic and metabolomic responses to connexin43 silencing in primary hepatocyte cultures. Archives of Toxicology, 2013, 87, 883-894.	1.9	12
131	Regulation of connexinâ€•and pannexinâ€•based channels by postâ€•translational modifications. Biology of the Cell, 2013, 105, 373-398.	0.7	57
132	The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies. Hepatology International, 2013, 7, 394-399.	1.9	2
133	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology, 2013, 87, 1315-1530.	1.9	1,089
134	IP3, a small molecule with a powerful message. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1772-1786.	1.9	49
135	Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Carcinogenesis, 2013, 34, 1393-1402.	1.3	52
136	The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation. Toxicology and Applied Pharmacology, 2013, 273, 484-491.	1.3	43
137	Proteomic analysis of global protein expression changes in the endothelin-1 rat model for cerebral ischemia: Rescue effect of mild hypothermia. Neurochemistry International, 2013, 63, 379-388.	1.9	14
138	The role of connexins and their channels in toxicity. Toxicology Letters, 2013, 221, S39.	0.4	0
139	The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology, 2013, 312, 158-165.	2.0	367
140	Primary hepatocyte cultures as prominent<i>in vitro</i>tools to study hepatic drug transporters. Drug Metabolism Reviews, 2013, 45, 196-217.	1.5	26
141	Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Research in Cardiology, 2013, 108, 309.	2.5	216
142	Paracrine signaling through plasma membrane hemichannels. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 35-50.	1.4	177
143	Purinergic signalling during sterile liver injury. Liver International, 2013, 33, 353-361.	1.9	6
144	Development of an Adverse Outcome Pathway From Drug-Mediated Bile Salt Export Pump Inhibition to Cholestatic Liver Injury. Toxicological Sciences, 2013, 136, 97-106.	1.4	111

#	Article	IF	Citations
145	Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers. Current Medicinal Chemistry, 2013, 20, 3011-3021.	1.2	40
146	Modifications in Connexin Expression in Liver Development and Cancer. Cell Communication and Adhesion, 2012, 19, 55-62.	1.0	23
147	Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment?. Critical Reviews in Toxicology, 2012, 42, 91-106.	1.9	21
148	Connexin43 Signaling Contributes to Spontaneous Apoptosis in Cultures of Primary Hepatocytes. Toxicological Sciences, 2012, 125, 175-186.	1.4	41
149	Comparison of hepatocarcinogen-induced gene expression profiles in conventional primary rat hepatocytes with in vivo rat liver. Archives of Toxicology, 2012, 86, 1399-1411.	1.9	23
150	Comparison of genotoxicant-modified transcriptomic responses in conventional and epigenetically stabilized primary rat hepatocytes with in vivo rat liver data. Archives of Toxicology, 2012, 86, 1703-1715.	1.9	15
151	Primary hepatocyte cultures as in vitro tools for toxicity testing: quo vadis?. Toxicology in Vitro, 2012, 26, 541-544.	1.1	20
152	Gap junctions and non-neoplastic liver disease. Journal of Hepatology, 2012, 57, 655-662.	1.8	29
153	Non-channel functions of connexins in cell growth and cell death. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2002-2008.	1.4	90
154	Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes. Investigational New Drugs, 2012, 30, 1715-1724.	1.2	14
155	Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Archives of Toxicology, 2012, 86, 405-412.	1.9	35
156	Connexins: Mediators, Targets and Biomarkers of Liver Toxicity. Pharmaceutica Analytica Acta, 2012, 03, .	0.2	1
157	Preservation of hepatocellular functionality in cultures of primary rat hepatocytes upon exposure to 4-Me2N-BAVAH, a hydroxamate-based HDAC-inhibitor. Toxicology in Vitro, 2011, 25, 100-109.	1.1	2
158	Effect of Trichostatin A on miRNA expression in cultures of primary rat hepatocytes. Toxicology in Vitro, 2011, 25, 1173-1182.	1.1	17
159	Connexins: sensors and regulators of cell cycling. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 13-25.	3.3	52
160	Critical selection of reliable reference genes for gene expression study in the HepaRG cell line. Biochemical Pharmacology, 2011, 81, 1255-1261.	2.0	26
161	Calcium and connexin-based intercellular communication, a deadly catch?. Cell Calcium, 2011, 50, 310-321.	1.1	64
162	Pannexin channels in ATP release and beyond: An unexpected rendezvous at the endoplasmic reticulum. Cellular Signalling, 2011, 23, 305-316.	1.7	93

#	Article	IF	Citations
163	Connexin Channels Provide a Target to Manipulate Brain Endothelial Calcium Dynamics and Bloodâ€"Brain Barrier Permeability. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1942-1957.	2.4	135
164	Modulation of connexin signaling by bacterial pathogens and their toxins. Cellular and Molecular Life Sciences, 2011, 68, 3047-3064.	2.4	23
165	Alternative (non-animal) methods for cosmetics testing: current status and future prospectsâ€"2010. Archives of Toxicology, 2011, 85, 367-485.	1.9	488
166	Characterization of spontaneous cell death in monolayer cultures of primary hepatocytes. Archives of Toxicology, 2011, 85, 1589-1596.	1.9	20
167	Towards an integrated in vitro strategy for repeated dose toxicity testing. Archives of Toxicology, 2011, 85, 365-366.	1.9	9
168	Role of connexin-related signalling in hepatic homeostasis and its relevance for liver-based in vitro modelling. World Journal of Gastrointestinal Pathophysiology, 2011, 2, 82.	0.5	6
169	Mathieu Vinkenâ€™s Work on the Role of Connexin-related Signalling in Hepatic Homeostasis and its Relevance for Liver-based In vitro Modelling. Pharmaceutica Analytica Acta, 2011, 02, .	0.2	3
170	Connexin32 hemichannels contribute to the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death. Cellular and Molecular Life Sciences, 2010, 67, 907-918.	2.4	31
171	Preliminary <i>In Vivo</i> Evaluation of [¹³¹I]-2-Iodo-<scp>D</scp>-Phenylalanine as a Potential Radionuclide Therapeutic Agent in R1M-Fluc Rhabdomyosarcoma Tumor-Bearing NuNu Mice Using Bioluminescent Imaging. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 225-231.	0.7	2
172	Effect of the Histone Deacetylase Inhibitor Trichostatin A on the Metabolome of Cultured Primary Hepatocytes. Journal of Proteome Research, 2010, 9, 413-419.	1.8	12
173	DNA methyltransferase 3a expression decreases during apoptosis in primary cultures of hepatocytes. Toxicology in Vitro, 2010, 24, 445-451.	1.1	13
174	Inhibition of Gap Junctional Intercellular Communication by Toxic Metals. Chemical Research in Toxicology, 2010, 23, 1862-1867.	1.7	31
175	Emerging roles of connexin hemichannels in gastrointestinal and liver pathophysiology. World Journal of Gastrointestinal Pathophysiology, 2010, 1, 115.	0.5	11
176	Biochemical Characterisation of an In Vitro Model of Hepatocellular Apoptotic Cell Death. ATLA Alternatives To Laboratory Animals, 2009, 37, 209-218.	0.7	11
177	Epigenetic regulation of gap junctional intercellular communication: More than a way to keep cells quiet?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 53-61.	3.3	29
178	Ca2+ regulation of connexin 43 hemichannels in C6 glioma and glial cells. Cell Calcium, 2009, 46, 176-187.	1.1	191
179	Role of epigenetics in liver-specific gene transcription, hepatocyte differentiation and stem cell reprogrammation. Journal of Hepatology, 2009, 51, 187-211.	1.8	66
180	Gap junctional intercellular communication as a target for liver toxicity and carcinogenicity. Critical Reviews in Biochemistry and Molecular Biology, 2009, 44, 201-222.	2.3	57

#	Article	IF	Citations
181	Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(Î²â€amino esters). Journal of Gene Medicine, 2008, 10, 783-794.	1.4	58
182	Biology and pathobiology of gap junctional channels in hepatocytes. Hepatology, 2008, 47, 1077-1088.	3.6	88
183	Junctional structures and hepatocellular carcinoma: from the lab to the clinic?. Liver International, 2008, 28, 432-434.	1.9	0
184	Differential effects of hydroxamate histone deacetylase inhibitors on cellular functionality and gap junctions in primary cultures of mitogen-stimulated hepatocytes. Toxicology Letters, 2008, 178, 37-43.	0.4	7
185	The carcinoGENOMICS project: Critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. Mutation Research - Reviews in Mutation Research, 2008, 659, 202-210.	2.4	60
186	Modulation of CYP1A1 and CYP2B1 expression upon cell cycle progression in cultures of primary rat hepatocytes. Toxicology in Vitro, 2007, 21, 1253-1257.	1.1	8
187	The novel histone deacetylase inhibitor 4-Me2N-BAVAH differentially affects cell junctions between primary hepatocytes. Toxicology, 2007, 236, 92-102.	2.0	21
188	Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Developmental Biology, 2007, 7, 24.	2.1	76
189	Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepatocytes. Toxicology and Applied Pharmacology, 2007, 218, 64-71.	1.3	45
190	Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy. Archives of Toxicology, 2007, 81, 533-544.	1.9	15
191	Rat Hepatocyte Cultures: <i>Conventional Monolayer and Cocultures With Rat Liver Epithelial Cells</i>. , 2006, 320, 239-246.		8
192	Rat Hepatocyte Cultures: <i>Collagen Gel Sandwich and Immobilization Cultures</i>. , 2006, 320, 247-254.		9
193	Hepatocytes in Suspension. , 2006, 320, 255-264.		12
194	Isolation of Rat Hepatocytes. , 2006, 320, 229-238.		78
195	Involvement of Cell Junctions in Hepatocyte Culture Functionality. Critical Reviews in Toxicology, 2006, 36, 299-318.	1.9	92
196	Connexins and their channels in cell growth and cell death. Cellular Signalling, 2006, 18, 592-600.	1.7	205
197	Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts. Current Drug Targets, 2006, 7, 773-787.	1.0	11
198	Molecular Mechanisms Underlying the Dedifferentiation Process of Isolated Hepatocytes and Their Cultures. Current Drug Metabolism, 2006, 7, 629-660.	0.7	253

#	Article	IF	Citations
199	Trichostatin A Enhances Gap Junctional Intercellular Communication in Primary Cultures of Adult Rat Hepatocytes. Toxicological Sciences, 2006, 91, 484-492.	1.4	56
200	Differential Effects of Histone Deacetylase Inhibitors in Tumor and Normal Cellsâ€"What Is the Toxicological Relevance?. Critical Reviews in Toxicology, 2005, 35, 363-378.	1.9	57